Top

Published in:

01-10-2012 | Short Communication

Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma

Authors: Claudio Cartoni, Gregorio Antonio Brunetti, Vincenzo Federico, Fabio Efficace, Sara Grammatico, Andrea Tendas, Laura Scaramucci, Luca Cupelli, Gianna Maria D’Elia, Andrea Truini, Pasquale Niscola, Maria Teresa Petrucci

Published in: Supportive Care in Cancer | Issue 10/2012

Abstract

Purpose

Bortezomib, a proteasome inhibitor drug very effective against multiple myeloma, may induce the so-called bortezomib-induced peripheral neuropathy (BIPN), hardly manageable with common analgesic drugs. This study assessed the effectiveness of controlled-release (CR) oral oxycodone in controlling pain and its interference on daily functions of patients with hematologic malignancies affected by BIPN.

Methods

Forty-six patients (median age, 62 years) affected by myeloma and lymphoma, complaining of BIPN-related pain of moderate-to-severe intensity and unresponsive to previous analgesic treatments, were treated with CR oxycodone. The intensity of continuous and brief pain (BP) along with interference of pain with the common daily dimensions of feeling and function were evaluated by using an 11-point numerical rating scale (NRS); a global patient evaluation of efficacy was also performed.

Results

The daily average dose of CR oxycodone administered was 28.46 mg (range, 20–80 mg). The pain intensity decreased from a mean NRS value of 7.6 at baseline to 1.3 on day 14. The frequency of BP was reduced from 61 to 47 % of patients and its intensity from 7.4 to 3.1 NRS score. A similar trend to decreasing values was observed for all the daily life functions. Slight- or mild-intensity side effects were observed in 23 patients (51 %). At the end of the study, 75 % of patients found the treatment effective or very effective.

Conclusion

CR oxycodone for relief of BIPN-related pain was effective and well tolerated. The pain control significantly improved also the quality of the daily life functions, which are usually compromised in these suffering patients.

Niscola P, Cartoni C, Romani C, Brunetti GA, D'Elia GM, Cupelli L, Tendas A, de Fabritiis P, Mandelli F, Foà R (2007) Epidemiology, features and outcome of pain in patients with advanced hematological malignancies followed in a home care program: an Italian survey. Ann Hematol 86(9):671–676PubMedCrossRef

Niscola P, Arcuri E, Giovannini M, Scaramucci L, Romani C, Palombi F, Trapè G, Morabito F (2004) Pain syndromes in haematological malignancies: an overview. Hematol J 5(4):293–303PubMedCrossRef

Niscola P, Romani C, Cartoni C, Cupelli L, Piccioni D, Dentamaro T, Tendas A, Giovannini M, Scaramucci L, Tolu B, Perrotti AP, de Fabritiis P (2008) Epidemiology of pain in hospital haematological setting: an Italian survey. Leuk Res 32(1):197–198PubMedCrossRef

Jensen TS, Gottrup H, Sindrup SH, Bach FW (2001) The clinical picture of neuropathic pain. Eur J Pharamacol 429:1–11CrossRef

Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I (2008) Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 13(4):275–282PubMedCrossRef

Argyriou AA, Iconomou G, Kalofonos HP (2008) Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112(5):1593–1599PubMedCrossRef

Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24(19):3113–3120PubMedCrossRef

San Miguel JF, Schlag R, Khuageva NK (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906–917PubMedCrossRef

Gerecitano J, Portlock C, Moskowitz C, Hamlin P, Straus D, Zelenetz AD, Zhang Z, Dumitrescu O, Sarasohn D, Lin D, Pappanicholaou J, Cortelli BM, Neylon E, Hamelers R, Wright J, O'Connor OA (2009) Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol 146(6):652–655PubMedCrossRef

10.

Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, Marmiroli P, Bossi M, Oggioni N, D'Incalci M, De Coster R (2007) Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 204(1):317–325PubMedCrossRef

11.

Cata JP, Weng HR, Burton AW, Villareal H, Giralt S, Dougherty PM (2007) Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 8(4):296–306PubMedCrossRef

12.

Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J (2008) Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 29;70(18):1630–1635CrossRef

13.

Cavaletti G, Nobile-Orazio E (2007) Bortezomib-induced peripheral neurotoxicity: still far from a painless gain. Haematologica 92(10):1308–1310PubMedCrossRef

14.

Jagannath S, Durie BG, Wolf JL, Camacho ES, Irwin D, Lutzky J, McKinley M, Potts P, Gabayan AE, Mazumder A, Crowley J, Vescio R (2009) Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol 146(6):619–626PubMedCrossRef

15.

Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J (2009) Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 144(6):895–903PubMedCrossRef

16.

Attal N, Cruccu G, Haanpää M, Hansson P, Jensen TS, Nurmikko T, Sampaio C, Sindrup S, Wiffen P, EFNS Task Force (2006) EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 13(11):1153–1169PubMedCrossRef

17.

Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice ASC, Stacey BR, Treede RD, Turk DC, Wallace MS (2007) Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 132:237–251PubMedCrossRef

18.

Jensen TS, Madsen CS, Finnerup NB (2009) Pharmacology and treatment of neuropathic pains. Curr Opin Neurol 22(5):467–474PubMedCrossRef

19.

Watson CP, Babul N (1998) Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 50(6):1837–1841PubMedCrossRef

20.

Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J (2003) Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 105(1–2):71–78PubMedCrossRef

21.

Niscola P, Perrotti AP, del Poeta G, Romani C, Palombi M, Piccioni D, Scaramucci L, Tolu B, Tendas A, Cupelli L, Abruzzese E, D'Elia GM, Brunetti GA, Maurillo L, Giovannini M, Cartoni C, de Fabritiis P (2007) Case reports: zoster pain in haematological malignancies: effective pain relief with oxycodone in patients unresponsive to other analgesic measures. Herpes 14(2):45–47PubMed

22.

Gatti A, Sabato AF, Occhioni R, Colini Baldeschi G, Reale C (2009) Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study. Eur Neurol 61(3):129–137PubMedCrossRef

23.

No authors listed. National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0 (CTCAE) Available from http://ctep.cancer.gov/forms/CTCv2

24.

Gilardini A, Marmiroli P, Cavaletti G (2008) Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity? Curr Med Chem 15:3025–3035PubMedCrossRef

25.

Bercovitch M, Adunsky A (2006) High dose controlled-release oxycodone in hospice care. J Pain Palliat Care Pharmacother 20(4):33–39PubMedCrossRef

26.

Niscola P, Scaramucci L, Romani C, Giovannini M, Maurillo L, del Poeta G, Cartoni C, Arcuri E, Amadori S, De Fabritiis P (2006) Opioids in pain management of blood-related malignancies. Ann Hematol 85(8):489–501PubMedCrossRef

Title: Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma
Authors: Claudio Cartoni
Gregorio Antonio Brunetti
Vincenzo Federico
Fabio Efficace
Sara Grammatico
Andrea Tendas
Laura Scaramucci
Luca Cupelli
Gianna Maria D’Elia
Andrea Truini
Pasquale Niscola
Maria Teresa Petrucci
Publication date: 01-10-2012
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 10/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-012-1511-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2012

Interviews with patients with advanced cancer—another step towards an international cancer pain classification system

Anticancer therapies in specialized palliative care—a multicenter survey

The management of procedural pain at the Italian Centers of Pediatric Hematology–Oncology: state-of-the-art and future directions

A pilot study to examine patient awareness and provider discussion of the impact of cancer treatment on fertility in a registry-based sample of African American women with breast cancer

Oral mucositis in pediatric and adolescent patients undergoing chemotherapy: the impact of symptoms on quality of life

Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer